ProKidney (NASDAQ:PROK – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Institutional and Insider Ownership
51.6% of ProKidney shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for ProKidney and Gossamer Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 1 | 1 | 1 | 1 | 2.50 |
| Gossamer Bio | 2 | 3 | 4 | 0 | 2.22 |
Risk & Volatility
ProKidney has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.
Valuation & Earnings
This table compares ProKidney and Gossamer Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $890,000.00 | 522.67 | -$68.99 million | ($0.53) | -2.91 |
| Gossamer Bio | $55.54 million | 0.72 | -$170.37 million | ($0.79) | -0.21 |
ProKidney has higher earnings, but lower revenue than Gossamer Bio. ProKidney is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ProKidney and Gossamer Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -8,131.50% | N/A | -21.39% |
| Gossamer Bio | -324.82% | N/A | -96.10% |
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
